ATG16L1 and digestive system neoplasm: The purpose of our studies was to define the interactions, if any, between aramchol and a multi-kinase inhibitor in GI tumor cells at clinically relevant drug concentrations and to define the responses of isogenic cells homozygous for ATG16L1 T300 or ATG16L1 A300 [18–23].